Alpha 2.0
Login Register
» Articles » PMID: 12718897

Progress Towards a Vaccine for Huntington's Disease

Overview
Journal Mol Ther
Publisher Cell Press
Specialties Molecular Biology
Pharmacology
Date 2003 Apr 30
PMID 12718897
Citations 6
Authors
Ruth Luthi-Carter
Affiliations
Soon will be listed here.
Citing Articles

Promises and pitfalls of immune-based strategies for Huntington's disease.

Colpo G, Furr Stimming E, Rocha N, Teixeira A Neural Regen Res. 2017; 12(9):1422-1425.

PMID: 29089980 PMC: 5649455. DOI: 10.4103/1673-5374.215245.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.

Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C Mol Neurodegener. 2015; 10:10.

PMID: 25886309 PMC: 4411775. DOI: 10.1186/s13024-015-0008-9.

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A Acta Neuropathol. 2014; 127(6):861-79.

PMID: 24525765 PMC: 4034750. DOI: 10.1007/s00401-014-1256-4.

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Valera E, Masliah E Pharmacol Ther. 2013; 138(3):311-22.

PMID: 23384597 PMC: 3925783. DOI: 10.1016/j.pharmthera.2013.01.013.

Drug targets from genetics: α-synuclein.

Danzer K, McLean P CNS Neurol Disord Drug Targets. 2011; 10(6):712-23.

PMID: 21838671 PMC: 3364517. DOI: 10.2174/187152711797247867.